As a leading provider of medical devices and solutions, Mindray is committed to delivering more value-added services and instilling greater confidence in our end-users. To fulfill this commitment, we proactively attend reputable external quality assessment (EQA) programmes and establish partnerships with third-party quality controls providers worldwide. These efforts aim to help assess the quality performance of laboratories, boost confidence in patient test results, and cut down on time and labor costs, all contributing to achieving accurate diagnosis and treatment for patients.
Mindray maintains a longstanding partnership with Randox for both internal and external quality assessment programmes. Over the years, Mindray has consistently participated in Randox International Quality Assessment Scheme (RIQAS), including Monthly Immunoassay Programme, Cardiac Programme, Serology (HIV/Hepatitis) Programme, Serology (Syphilis) Programme, Serology (ToRCH) Programme, Immunoassay Speciality 1 Programme, Immunoassay Speciality 2 Programme, HbA1c Programme and Clinical Chemistry Programme.
We are proud to announce that our participation in RIQAS has yielded significant achievements thus far.
Mindray's commitment to quality is reflected in our excellent performance in RIQAS programmes, as well as our partnership with Randox for third-party quality controls. As a result of this partnership, a range of controls in the Acusera portfolio now includes values for Mindray series instruments. This development is significant, as it allows laboratories to ensure the accuracy and reliability of their testing procedures across a wider range of instruments.
The partnership between Mindray and Randox combines our strengths and expertise to provide laboratories worldwide with a comprehensive range of high-quality diagnostic solutions, including reagents, quality controls, and EQA programmes.
